If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
Afc Gamma, Inc. (AFCG)
Property Solutions Acquisition II (PSAGU)
Khosla Ventures Acquisition Co. (KVSA)
Twin Ridge Capital Acquisition (TRCA.U)
Rxr Acquisition (RXRAU)
Interprivate II Acquisition (IPVA.U)
Interprivate III Financial Partners (IPVF.U)
Aurora Acquisition Corp. (AURCU)
Lerer Hippeau Acquisition Corp. (LHAA)
Universe Pharmaceuticals (UPC)
Roblox Corporation (RBLX)
First High-school Education Group Co., Ltd. (FHS)
Coupang, Inc. (CPNG)
Hayward Holdings, Inc. (HAYW)
Priced IPO
Innovage Holding Corp (INNV)
Oscar Health, Inc. (OSCR)
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
More companies

Scopus BioPharma (SCPS)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

They are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Their mission is to improve patient outcomes and save lives. To achieve their mission, they are capitalizing on groundbreaking scientific and medical discoveries at some of the world’s foremost research and academic institutions. Their lead development program is a novel, first-in-class, targeted immuno-oncology gene therapy for the treatment of multiple cancers. They have partnered with City of Hope, or COH, for CpG-STAT3siRNA, a STAT3 inhibitor gene therapy. In pre-clinical testing at City of Hope, their STAT3 inhibitor has successfully reduced growth and metastasis of various pre-clinical tumor models, including melanoma, and colon and bladder cancers, as well as leukemia and lymphoma. An investigational new drug application, or IND, for their STAT3 inhibitor for B-cell lymphoma is currently anticipated to be filed with the United States Food and Drug Administration, or FDA, in Q4 2020. They currently anticipate that a first-in-human Phase 1 clinical trial for B-cell lymphoma will commence in Q1 2021.
Employees Founded
5 2017


IPO information

Expected Date 12/16/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 1
Shares Revised (MM) 0.5
Expected offer amount (MM) $6
Realized offer amount(MM) $2.75

Financial Data (last reporting year)

Market Cap (MM) -
Revenues (MM) -
Net Income (Loss) (MM) -


What do you think will happen with the SCPS share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img

Sector: Healthcare

Tweets about $SCPS

Tweets volume:

RT volume:


Google Trends Stats